# Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

> **NCT01567059** · PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Acute Myeloid Leukemia With Multilineage Dysplasia
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Del(5q)
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- de Novo Myelodysplastic Syndromes
- Previously Treated Myelodysplastic Syndromes
- Secondary Acute Myeloid Leukemia
- Secondary Myelodysplastic Syndromes
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** tosedostat
- **DRUG:** cytarabine
- **DRUG:** decitabine

## Key facts

- **NCT ID:** NCT01567059
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2017-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01567059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01567059, "Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01567059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*